Across TCGA pan-cancer cohorts, IGHVII-22-1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of IGHVII-22-1’s most consistent transcriptional readouts.
The strongest signal is observed in stomach adenocarcinoma (STAD), where IGHVII-22-1 RNA is repressed in tumor relative to normal tissue. In most cancer types IGHVII-22-1 is over-expressed in tumor, although a few such as STAD show the opposite, repressed pattern.
STAD and LUAD are the cancer types where IGHVII-22-1 tumor–normal differential expression is most reproducible.